current circumstances, if pharmaceutical companies are to maintain existing
trials – or satisfactorily recruit for new trials – they must consider adopting
decentralized models, delivering treatment Direct-to-Patient (DtP), gathering
data from participants’ homes.
sponsors took this step during the first
wave of the pandemic. World Courier examines how DtP has developed and the lessons
we have learnt as a result.
this whitepaper to learn more about:
acceptance around the world
experience vs sponsor experience
processes for a decentralized future